Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/16/22
Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in AfricaPRNewsWire • 12/14/22
The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, AmgenInvestors Business Daily • 12/13/22
Eli Lilly sets guidance for 2023 and stock falls as EPS lags current consensusMarket Watch • 12/13/22
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New MedicinesPRNewsWire • 12/13/22
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual MeetingPRNewsWire • 12/12/22
How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — AgainInvestors Business Daily • 12/09/22
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetesPRNewsWire • 12/07/22
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetesBusiness Wire • 12/07/22
Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet OncologyPRNewsWire • 12/06/22